> Detailanzeige

Dorobantu, Maria; Cojocaru, Cosmin; Stanciulescu, Laura; Pop, Calin; Bala, Cornelia; Benedek, Theodora; Parepa, Irinel; Lighezan, Daniel; Darabont, Roxana; Darabantiu, Dan; Mitu, Florin; Gheorghita, Valeriu; Scafa-Udriste, Alexandru; Gheorghe-Fronea, Oana-Florentina

Ups and downs of conducting a national representative survey on hypertension during pandemic time: main results of SEPHAR IV

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Ups and downs of conducting a national representative survey on hypertension during pandemic time: main results of SEPHAR IV
  • Beteiligte: Dorobantu, Maria; Cojocaru, Cosmin; Stanciulescu, Laura; Pop, Calin; Bala, Cornelia; Benedek, Theodora; Parepa, Irinel; Lighezan, Daniel; Darabont, Roxana; Darabantiu, Dan; Mitu, Florin; Gheorghita, Valeriu; Scafa-Udriste, Alexandru; Gheorghe-Fronea, Oana-Florentina
  • Erschienen: Ovid Technologies (Wolters Kluwer Health), 2023
  • Erschienen in: Journal of Hypertension
  • Sprache: Englisch
  • DOI: 10.1097/hjh.0000000000003461
  • ISSN: 0263-6352; 1473-5598
  • Schlagwörter: Cardiology and Cardiovascular Medicine ; Physiology ; Internal Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>Objectives:</jats:title> <jats:p>This national representative survey sought to assess hypertension's prevalence, awareness, treatment and control in Romania.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>A representative sample (by age, sex and residence) of 1477 Romanian adults (51.19 ± 16.61 years, range 18–80 years, 59.9% women) was multimodally evaluated during two study visits. Hypertension was defined as SBP at least 140 mmHg and/or DBP at least 90 mmHg or previously diagnosed hypertension, regardless of BP. Awareness was defined by knowledge of previous hypertension diagnosis or of current use of antihypertensive treatment. Treatment was defined by antihypertensive medication taken at least 2 weeks prior to enrolment. Control was defined as SBP less than 140 mmHg and DBP less than 90 mmHg at both visits in treated hypertensive patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Hypertension prevalence was 46% (<jats:italic toggle="yes">n</jats:italic> = 680) consisting of 81.02% (<jats:italic toggle="yes">n</jats:italic> = 551) known hypertensive patients and 18.98% (<jats:italic toggle="yes">n</jats:italic> = 129) newly diagnosed hypertensive patients. Awareness, treatment and control of hypertension were: 81% (<jats:italic toggle="yes">n</jats:italic> = 551), 83.8% (<jats:italic toggle="yes">n</jats:italic> = 462) and 39.2% (<jats:italic toggle="yes">n</jats:italic> = 181).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>Despite numerous pandemic-related obstacles in conducting a national survey, SEPHAR IV updates hypertension epidemiological data of a high-cardiovascular-risk Eastern-European population. This study confirms previous predictions of hypertension prevalence, treatment and control, which remain unfavourable because of unsatisfactory control of promoting factors.</jats:p> </jats:sec>